MDMB-CHMINACA

Leave a Comment / Indazole based / By

Summary

MDMB-CHMINACA, also recognized as MDMB(N)-CHM, is an indazole-derived synthetic cannabinoid renowned for its robust affinity as a CB1 receptor agonist. This compound has gained notoriety as an online designer drug. Originally developed by Pfizer in 2008, MDMB-CHMINACA is among the most potent cannabinoid agonists, boasting an impressive binding affinity of 0.0944 nM at the CB1 receptor, with an EC50 of 0.330 nM.[7] Notably, it shares a close relationship with MDMB-FUBINACA, an infamous substance linked to over 1,000 hospitalizations and 40 fatalities in Russia due to intoxication.

Identifiers
IUPAC name
CAS Number1185888-32-7
PubChem CID121491808
ChemSpider32055574
UNIIZ6EXBVG316
CompTox Dashboard (EPA)DTXSID001010034
Chemical and physical data
FormulaC22H31N3O3
Molar mass385.508 g·mol−1

Legal status

MDMB-CHMINACA was classified as a controlled substance under the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore starting in May 2015.
As of December 2015, MDMB-CHMINACA has been deemed illegal in Germany and Switzerland.
On September 25, 2019, Sweden’s public health agency recommended the classification of MDMB-CHMINACA as a hazardous substance.

FAQ

  • What is MDMB-CHMINACA?
  • MDMB-CHMINACA is a synthetic cannabinoid known for its potent CB1 receptor agonist properties. It is part of a class of chemicals designed to mimic the effects of cannabinoids found in cannabis.
  • Is MDMB-CHMINACA legal?
  • The legal status of MDMB-CHMINACA varies by country. It is essential to check your local laws and regulations, as it may be a controlled substance in some places.
  • What are the effects of MDMB-CHMINACA?
  • The effects of MDMB-CHMINACA can include relaxation, altered perception, and increased heart rate. However, it may also lead to adverse effects such as anxiety, paranoia, and health risks.
  • Is MDMB-CHMINACA safe to use?
  • The safety of using MDMB-CHMINACA must be well-documented, and it may pose health risks. The purity and safety of products containing this substance can vary due to a lack of regulation.
  • How is MDMB-CHMINACA consumed?
  • MDMB-CHMINACA is typically inhaled as a vapour, but it can also be ingested or used in other ways. The method of use and dosage can significantly affect the potential risks and effects.
  • Is MDMB-CHMINACA addictive?
  • Synthetic cannabinoids like MDMB-CHMINACA can be habit-forming, and some individuals have reported withdrawal symptoms when discontinuing use. The potential for addiction varies from person to person.
  • Can MDMB-CHMINACA be detected in drug tests?
  • MDMB-CHMINACA and similar synthetic cannabinoids might not be detected in standard drug tests. Specialized tests may be required to identify their presence.
  • Are there health risks associated with MDMB-CHMINACA?
  • Yes, there are health risks associated with MDMB-CHMINACA use. These risks may include cardiovascular problems, anxiety, paranoia, and other adverse psychological effects.
  • Can MDMB-CHMINACA be used for medical purposes?
  • MDMB-CHMINACA is not approved for medical use nor considered a safe or effective treatment for any medical condition. It is strictly intended for research purposes.
  • Where can I get help or more information about MDMB-CHMINACA?
  • If you have concerns about MDMB-CHMINACA or need assistance with substance abuse, seek help from a medical professional, addiction specialist, or helpline. Additionally, reliable sources such as government health agencies can provide information on the potential risks associated with this substance.

References

  1. Banister SD, Longworth M, Kevin R, Sachdev S, Santiago M, Stuart J, et al. (September 2016) – “Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.” Published in ACS Chemical Neuroscience, Volume 7, Issue 9, Pages 1241–1254. DOI: 10.1021/acschemneuro.6b00137. PMID: 27421060.
  2. “MDMB-CHMINACA” – Information available at Cayman Chemical. Retrieved on 14 July 2015.
  3. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Shafran Y, Morzherin Y, Lebedev AT (August 2015) – “Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing an N-1-methoxycarbonylalkyl group.” Published in Analytical and Bioanalytical Chemistry, Volume 407, Issue 21, Pages 6301–6315. DOI: 10.1007/s00216-015-8612-7. PMID: 25893797. S2CID: 31838655.
  4. Prof. SA Savchuk (2014) – “Detection methods of psychoactive substances and liquid chromatography detection of metabolites” (PDF) (in Russian). Published by the Russian Ministry of Health. Retrieved on 14 July 2015.
  5. “Идентификация синтетических каннабимиметиков MDMB-CHMINACA, MDMB-FUBINACA и их метаболитов” (in Russian). Available from CTS “SCIENCE.” Retrieved on 14 July 2015.
  6. Hess C, Murach J, Krueger L, Scharrenbroch L, Unger M, Madea B, Sydow K (May 2017) – “Simultaneous detection of 93 synthetic cannabinoids by liquid chromatography-tandem mass spectrometry and retrospective application to real forensic samples.” Published in Drug Testing and Analysis, Volume 9, Issue 5, Pages 721–733. DOI: 10.1002/dta.2030. PMID: 27400642.
  7. Buchler IP et al – “INDAZOLE DERIVATIVES.” Published in WO 2009/106980.
  8. “Очередная жертва спайса” (in Russian). Published by the Federal Drug Control Service of the Russian Federation. Date: 17 March 2015. Archived from the original on 14 July 2015. Retrieved on 13 July 2015.
  9. “CNB NEWS RELEASE.” Published by the Central Narcotics Bureau (CNB). Date: 30 April 2015. Archived from the original on 15 July 2015. Retrieved on 14 July 2015.
  10. “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Available from Der Bundesrat.
  11. “Tretton ämnen föreslås klassas som narkotika eller hälsofarlig vara” (in Swedish). Published by Folkhälsomyndigheten on 25 September 2019.

Leave a Comment

Your email address will not be published. Required fields are marked *